# Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

> **NCT07150403** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 74 (estimated)

## Conditions studied

- Metastatic Colorectal Carcinoma (mCRC)

## Interventions

- **DRUG:** Oxaliplatin intravenous
- **DRUG:** 5 FU bolus
- **DRUG:** Folinic acid
- **DRUG:** 5 FU continuous
- **DRUG:** Irinotecan
- **DRUG:** FRUQUINTINIB
- **DRUG:** BEVACIZUMAB

## Key facts

- **NCT ID:** NCT07150403
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-10-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150403, "Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07150403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*